

1300 Eye Street N.W.
Washington, DC 20005
Telephone: 202.659.0100
Facsimile: 202.659.0105
www.novakdruce.com

RECEIVED
CENTRAL FAX CENTER
SEP 08 2006

Novak Druce &
Quigg LLP

Facsimile

To: USPTO – Mail Stop Amendment From: Todd R. Samelman

Fax: (571) 273-8300 Pages: 5

Phone: (571) 272-1000 Date: September 8, 2006

In re Application of: DAHLQVIST et al.

Serial No.: 09/537,710

Attorney Docket No.: 3377/99

Confirmation No.: 9098

Filing Date: 03/30/2000

Attachments: Reply to the Notice of Non-Compliant Amendment of August 09, 2006

CONFIDENTIALITY NOTICE: This facsimile and any attachments contain information from the law firm of Novak Druce & Quigg, LLP, which may be confidential and/or privileged. The information is intended to be for the use of the individual or entity named on this facsimile. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of the contents of this facsimile is prohibited. If you receive this facsimile in error, please notify us by reply facsimile immediately so that we can arrange for the retrieval of the original documents at no cost to you.

RECEIVED
CENTRAL FAX CENTER

SEP 08 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No. :	09/537,710	Confirmation No.:	9098
Applicant :	DAHLQVIST et al.	TC/A.U. :	1656
Filed :	30 March 2000	Customer No.:	26474
Examiner :	ROBINSON	Docket No. :	3377/99

NEW CLASS OF ENZYMES IN THE BIOSYNTHETIC PATHWAY FOR THE PRODUCTION OF TRIACYLGLYCEROL AND RECOMBINANT DNA MOLECULES ENCODING THESE ENZYMES

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

Certificate of Transmission

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 571-2738300 on Sep 8, 2006

Mosiolek
SIMONIR MOSIOLEK

AMENDMENT AND REQUEST FOR RECONSIDERATION

Honorable Sir:

This Amendment and Request for Reconsideration is in response to the Notice of Non-Compliant Amendment of 09 August 2006. Please amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.